# US 2015/0148356 A1 · Compounds for dry skin and anti-ageing application

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148356 A1
- Document ID: US20150148356A1
- Status: Published application
- Kind: A1
- Application number: 14/406,365
- Filed: 2013-06-05
- Published: 2015-05-28
- Earliest claimed: 2012-06-06
- Assignees: L'oreal
- Applicants: L'oreal
- Inventors: Xavier Marat; Benoit Muller; Agnès Thomas-Collignon; Dominique Bernard
- Web page: https://patentgrep.com/patent/US20150148356A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 8/4953: {containing pyrimidine ring derivatives, e.g. minoxidil}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61Q 19/007: {Preparations for dry skin}
- A61Q 19/08: Anti-ageing preparations
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to the cosmetic use, as agent for preventing and/or treating an aesthetic defect in the skin and/or its appendages that is associated with an imbalance in the differentiation and/or proliferation of the cells of an epidermis, of an effective amount of at least one compound represented by one of the general formulae, (Ia) or (Ib)

## Claims

### Claim 1

Cosmetic method for preventing and/or treating an aesthetic defect in the skin and/or its appendages that is associated with an imbalance in the differentiation and/or proliferation of the cells of an epidermis in an individual in need thereof, comprising at least one step of administering to said individual at least an effective amount of at least one compound represented by one of the general formulae, (Ia) or (Ib):
in which:
R1 represents H; —C(O)R10, with R10 being a saturated or unsaturated, linear or branched C1-C4 alkyl, or being a phenyl;
R2 represents H; a saturated or unsaturated, linear or branched C1-C12 alkyl group; or a group selected from:
in which R5, R6, R7, R8 and R9 represent, independently of one another, H; —NO2; —OH; OR10; —CN; a fluorine; Cl; I; Br; —CF3; a saturated or unsaturated, linear or branched C1-C4 alkyl; a phenyl; —OC(O)—R10; —O-Ph-X with X representing H, —OH, —NO2, a fluorine, a saturated or unsaturated, linear or branched C1-C4 alkoxy or alkyl; with R10 being as defined above,
R3 represents a group —OR11, with R11 being H, a saturated or unsaturated, linear or branched C1-C4 alkyl, or a phenyl,
R4 represents a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl,
R and R′, which are identical or different, represent H or a linear or branched C1-C4 alkyl,
or a physiologically acceptable salt of said compound.

### Claim 2 (depends on 1)

Method according to claim 1, in which said compound is of general formula (Ia) in which:
R1 represents H,
R2 represents H; a saturated or unsaturated, linear or branched C1-C12 alkyl group; or a group selected from:
in which R5, R6, R7, R8 and R9 represent, independently of one another, H; —NO2; —OH; OR10; —CN; a fluorine; Cl; I; Br; —CF3; a saturated or unsaturated, linear or branched C1-C4 alkyl; a phenyl; —OC(O)—R10; —O-Ph-X with X representing H, —OH, —NO2, a fluorine, a saturated or unsaturated, linear or branched C1-C4 alkoxy or alkyl;
R3 represents a group OR11,
R4 represents a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl,
R10 represents a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl, and R11 represents H; a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl,
R and R′, which are identical or different, represent H or a methyl,
or a physiologically acceptable salt of said compound.

### Claim 3 (depends on 1)

Method according to claim 1, in which said compound is of general formula (Ia) in which:
R1 represents H,
R2 represents H; a saturated or unsaturated, linear or branched C1-C12 alkyl group; or a group selected from:
in which R5, R6, R7, R8 and R9 represent, independently of one another, H; —OH; OR10; —CN; a saturated or unsaturated, linear or branched C1-C4, or even C2-C3, alkyl; or a phenyl;
R3 represents a group-OR11,
R4 represents a saturated, linear or branched C1-C4 alkyl,
R10 represents a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl, and R11 represents H; a saturated or unsaturated, linear or branched C1-C4 alkyl; or a phenyl,
R and R′, which are identical or different, represent H or a methyl,
or a physiologically acceptable salt of said compound.

### Claim 4 (depends on 1)

Method according to claim 1, in which said compound is of general formula (Ia) in which:
R1 represents H,
R2 represents H, a saturated or unsaturated, linear or branched C1-C6 alkyl group,
R3 represents a group —OR11, with R11 being H, or a linear or branched C1-C4, alkyl,
R4 represents a methyl,
R and R′ represent a methyl,
or a physiologically acceptable salt of said compound.

### Claim 5 (depends on 1)

Method according to claim 1, in which said compound is selected from:
or a physiologically acceptable salt of said compound.

### Claim 6 (depends on 1)

Method according to claim 1, in which said compound is employed at from 0.01 to 10% by weight, preferably from 0.1 to 5% by weight, relative to the total weight of the composition comprising it.

### Claim 7 (depends on 1)

Method according to claim 1, for preventing and/or treating aged skin and/or cutaneous signs of ageing, a disorder of the barrier function of the epidermis, or a dry skin and/or signs of skin dryness.

### Claim 8 (depends on 1)

Method according to claim 1, for preventing, reducing and/or treating wrinkles, fine lines or a deterioration in the microrelief.

### Claim 9 (depends on 1)

Method according to claim 1, for reinforcing the mechanical properties of the skin, more particularly for combating withered, flabby, slackened, sunken and/or emaciated skin, and/or for reinforcing and/or restoring the elasticity or firmness of the skin.

### Claim 10 (depends on 1)

Method according to claim 1, in which the cutaneous signs of ageing are selected from emaciation of the skin, a loss of firmness, a loss of elasticity, a loss of density, or a loss of tonicity in the skin, the appearance of a marked microrelief of the skin, the formation and/or presence of fine lines and/or wrinkles, a deterioration in the complexion of the skin, a wizened appearance of the skin, a deterioration in the odour of the skin, a sinking of the skin, or a withering of the skin.

### Claim 11 (depends on 1)

Method according to claim 1, for preventing and/or treating senile or fragile dry skin, or xerosis, selected in particular from common xerosis, senile xerosis, and winter xerosis.

### Claim 12 (depends on 1)

Method according to claim 1, for preventing and/or treating dry skin-associated itching and/or pulling sensations.

### Claim 13 (depends on 1)

Method according to claim 1, in which the signs of skin dryness are selected from withered skin, lack of elasticity, suppleness and/or tone in the skin, coarse feel, the presence of cracks, desquamation, the presence of scales, or dry skin-associated wrinkles and fine lines.

### Claim 14 (depends on 1)

Compound as defined according to claim 1, in an amount effective in a pharmaceutical or dermatological composition, for preventing and/or treating pathological constitutional dry skin selected from atopic dermatitis and ichthyosis.

### Claim 15

(canceled)

### Claim 16

Compound represented by the general formula (IIa):
in which:
R1 represents H, and
R2 represents a saturated, linear or branched C1-C4 alkyl; or
in which R5, R6, R7, R8 and R9 represent, independently of one another, H; —OH; OR10, with R10 representing a saturated or unsaturated, linear or branched C1-C4 alkyl, or a phenyl,
R3 represents a group —OR11, with R11 representing H, or a saturated or unsaturated, linear or branched C1-C2 alkyl;
R4 represents a saturated, linear or branched C2-C4 alkyl,
R and R′, which are identical or different, represent H or a methyl,
or a physiologically acceptable salt of said compound.

### Claim 17

Compound selected from:
or a physiologically acceptable salt of said compound.

### Claim 18 (depends on 16)

Cosmetic or dermatological composition comprising, in a physiologically acceptable medium, an effective amount of at least one compound as defined in claim 16.

### Claim 19 (depends on 17)

Cosmetic or dermatological composition comprising, in a physiologically acceptable medium, an effective amount of at least one compound as defined in claim 17.
